Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1988 1
1989 1
2004 1
2006 1
2008 1
2009 3
2010 2
2011 1
2012 4
2013 1
2014 2
2015 3
2019 1
2021 1
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
Teachey DT, Devidas M, Wood BL, Chen Z, Hayashi RJ, Hermiston ML, Annett RD, Archer JH, Asselin BL, August KJ, Cho SY, Dunsmore KP, Fisher BT, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju AI, Lam A, Messinger YH, Miles RR, Okada M, Patel SI, Schafer ES, Schechter T, Singh N, Steele AC, Sulis ML, Vargas SL, Winter SS, Wood C, Zweidler-McKay P, Bollard CM, Loh ML, Hunger SP, Raetz EA. Teachey DT, et al. J Clin Oncol. 2022 Jul 1;40(19):2106-2118. doi: 10.1200/JCO.21.02678. Epub 2022 Mar 10. J Clin Oncol. 2022. PMID: 35271306 Free PMC article. Clinical Trial.
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y, Gokani K, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kwok J, Lambe T, Libri V, Llewelyn MJ, McGregor AC, Minassian AM, Moore P, Mughal M, Mujadidi YF, Murira J, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Salkeld J, Saralaya D, Sharma S, Sheridan R, Sturdy A, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Nguyen-Van-Tam JS, Snape MD, Liu X, Faust SN; COV-BOOST study group. Munro APS, et al. Lancet. 2021 Dec 18;398(10318):2258-2276. doi: 10.1016/S0140-6736(21)02717-3. Epub 2021 Dec 2. Lancet. 2021. PMID: 34863358 Free PMC article. Clinical Trial.
Acquired immunodeficiency syndrome.
Freedman D, Shattock A, Stuart J, McLaughlin H. Freedman D, et al. Ir Med J. 1989 Sep;82(3):135-8. Ir Med J. 1989. PMID: 2599843
Accuracy of a Self-Administered Online Cognitive Assessment in Detecting Amnestic Mild Cognitive Impairment.
Paterson TSE, Sivajohan B, Gardner S, Binns MA, Stokes KA, Freedman M, Levine B, Troyer AK. Paterson TSE, et al. J Gerontol B Psychol Sci Soc Sci. 2022 Feb 3;77(2):341-350. doi: 10.1093/geronb/gbab097. J Gerontol B Psychol Sci Soc Sci. 2022. PMID: 34333629 Free PMC article.
The BHA model classified fewer participants into the inconclusive category and more as negative for aMCI, compared to the MoCA model (Stuart-Maxwell p = .004). DISCUSSION: The self-administered BHA provides similar detection of aMCI as a clinician-administered screener (Mo …
The BHA model classified fewer participants into the inconclusive category and more as negative for aMCI, compared to the MoCA model (Stu …
Effect of in-painting on cortical thickness measurements in multiple sclerosis: A large cohort study.
Govindarajan KA, Datta S, Hasan KM, Choi S, Rahbar MH, Cofield SS, Cutter GR, Lublin FD, Wolinsky JS, Narayana PA; MRI Analysis Center at Houston; CombiRx Investigators Group. Govindarajan KA, et al. Hum Brain Mapp. 2015 Oct;36(10):3749-3760. doi: 10.1002/hbm.22875. Epub 2015 Jun 19. Hum Brain Mapp. 2015. PMID: 26096844 Free PMC article. Clinical Trial.
GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study.
Goodman AD, Rossman H, Bar-Or A, Miller A, Miller DH, Schmierer K, Lublin F, Khan O, Bormann NM, Yang M, Panzara MA, Sandrock AW; GLANCE Investigators. Goodman AD, et al. Neurology. 2009 Mar 3;72(9):806-12. doi: 10.1212/01.wnl.0000343880.13764.69. Neurology. 2009. PMID: 19255407 Free PMC article. Clinical Trial.
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Radue EW, et al. J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16. J Neurol Sci. 2010. PMID: 20236661 Clinical Trial.
25 results